Chartwell Partners recruited industry executive and neurologist, Chris Kenney, MD, as Chief Medical Officer for Xenon Pharmaceuticals, a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Most recently, Dr. Kenney served as Chief Medical Officer for Cadent Therapeutics, a company focused on developing positive allosteric modulators for the treatment of cognitive, mood, and movement disorders. Cadent was acquired by Novartis in 2021. Previously, Dr. Kenney served in leadership positions with Acorda Therapeutics, Biotie Therapies, Novartis and Merck Serono.
For more information on this appointment, please visit: https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceuticals-strengthens-leadership-team-appointment-dr